Discover What's Next in Biopharma M&A and Licensing The 2025 Dealmakers' Intentions Survey is here! Now in its 15th year, this report offers a forward-looking view of dealmaking trends, investment hotspots and key factors shaping the biopharmaceutical landscape in the year ahead.
Inside, you'll find: A retrospective on 2024 deal activity—and why it was the slowest in a decade Insights into 2025 dealmaker sentiment: Will M&A and financing recover? The top therapy areas and technologies capturing investor interest A deep dive into oncology, genetic medicine and AI-driven deal opportunities Expert perspectives on deal hurdles, including valuation gaps and financing challenges Whether you're a buyer, seller or investor, this report provides the data and strategic insights you need to navigate 2025's evolving deal landscape.
Download your copy now to stay ahead in biopharma dealmaking. Access the Report | 